MarketInOut Stock Screener Log In | Sign Up
 

OmniAb Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
OmniAb Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization668.8 mln
Float119 mln
Earnings Date10/30/2026

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

-1.38
Manipulation likely

1-Year Forecast

8.33
Transformational upside

Relative Strength

44 / 100
Slightly lagging

Debt / Equity

0.07
Debt-free

Pre-Tax Margin

-119%
Severely loss-making

Business Description

OmniAb is a California-based biotechnology company that licenses its antibody discovery technology to drug developers and research institutions across the United States, Europe, Asia, and Canada. The company uses a suite of specially engineered animals ? including modified rats, mice, chickens, and cattle ? whose immune systems have been designed to produce antibodies suitable for human medicines. These biological tools are supported by artificial intelligence and machine learning software to help partners find and refine the best possible drug candidates. Founded in 2012 and headquartered in Emeryville, OmniAb works with partners at every stage of early drug discovery to accelerate the development of new treatments.

Key Fundamentals

EPS-0.36
ROE-16.65
RPS0.31
ROIC-18.44
ROA-14.54
EBITDA, mln-21.92
EV / EBITDA-29.53
EV / EBIT-14.16
Revenue, mln38.46
EV / Revenue16.83

Quote Details

Last 4.66
Change -0.12 (-2.51%)
Open 4.70
Volume 1,278,870
Turnover 5,959,534
Average Volume 1,355,788

Financial Ratios

Pre-Tax Profit Margin-119
Leverage Ratio1.12
Current Ratio4.80
Price / Book2.77
Price / Tangible Book12.10
Debt / Equity0.07
Price / Sales16.45

Financial Strength

Altman Z-Score12.75
Piotroski F-Score 6 / 9
Beneish M-Score-1.38
1-Year Target Price8.33
Short Ratio5.60
Short % of Float6.19

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.53% 76 / 100   
1 Month -2.71% 48 / 100   
2 Months 124% 99 / 100   
6 Months 219% 100 / 100   
1 Year 182% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog